Restoring oxygen consumption in colon cells may limit pathological clones after regeneration
Late, local mesalazine may restore oxygen consumption by mature colon cells, limiting bacterial respiratory growth, repeated injury and tumour-related deaths. Protection persisting when oxygen availability and bacterial respiration are experimentally held fixed would refute the hypothesis.
Stage of verification
- Hypothesis published2026-10-05
- Indirect evidenceAssessed at 5 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
The biological function description is being prepared
Lens
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Metabolism and energy
Oxidative metabolism
Metabolic processes that consume oxygen, including the oxidation of fatty acids
Where this hypothesis actsMature colonocytes after intestinal repair, when a prolonged regenerative programme leaves more oxygen for bacteria
Hypotheses on this target 1
Inhibition
Activation1
Function preservation
Supplementation
Feedback restoration
Direct measurement
What is proposed
Activation
Restore oxygen consumption through oxidative metabolism
With whatSmall molecule
HowLocal, late mesalazine treatment, with tests of dependence on PPARγ and colonocyte oxidative metabolism
Possible result
Possible reduction in bacterial respiratory growth, repeated inflammatory injury and tumour mortality
From the recordМиметик завершения регенерации может ограничивать патологические клоны через восстановление потребления кислорода зрелыми колоноцитами.
Metabolite or ion
Oxygen
A molecule consumed during oxidative metabolism and available to bacteria for respiratory growth
Where this hypothesis actsThe intestinal environment after repair, where prolonged regeneration increases oxygen availability to bacteria
Hypotheses on this target 1- Supplementation
Accelerated excretion
Composition restoration
What is proposed
Restore low oxygen availability to intestinal bacteria
With whatNot stated in the record
HowRestore oxygen consumption by mature colonocytes; an independent oxygen-restoration intervention is also proposed but not specified
Possible result
Possible restoration of protection when colonocyte oxidative metabolism is suppressed
From the recordНезависимое восстановление низкой доступности кислорода вернёт защиту.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Finishing tissue repair may matter for longer life as much as starting it. The unexpected move is to change how much oxygen repaired gut cells leave available to bacteria, rather than simply increase tissue growth. This pipeline-generated hypothesis proposes late, local treatment with mesalazine, the candidate drug, to restore that balance; it does not report a measured benefit after repair or an increase in lifespan.
- Prolonged repair is proposed to keep colon cells in a state that leaves more oxygen available to gut bacteria.
- Late, local mesalazine treatment is proposed to shift repaired cells from that persistent repair state back to the mature state that uses fatty acids as fuel and consumes oxygen, with dependence on PPARγ to be tested.
- Renewed oxygen consumption by colon cells is predicted to lower the oxygen available to nearby bacteria.
- Lower oxygen is predicted to remove the growth advantage of facultative anaerobes, bacteria that can grow without oxygen but can also use it to support growth.
- Reduced oxygen-supported bacterial growth is predicted to lessen repeated inflammatory injury.
- Less repeated injury is predicted to limit expansion of abnormal cell groups.
- Reduced abnormal cell expansion is proposed to lower deaths from tumors and potentially extend life.
A workshop starts using a shared supply again after repairs, leaving less surplus for troublesome occupants next door. The proposed benefit comes from using the supply in the right place, rather than directly attacking those occupants.
Where the picture breaks: Oxygen is not a fixed stock divided between two rooms, and bacteria differ in how they use it. The picture does not establish that changing oxygen availability prevents repeated injury, abnormal cell expansion or death.
- Master questionstep 01 of 04
Reproducing selected natural processes with drugs, combinations or other interventions could offer new ways to extend life.
Rests on: The goal explicitly calls for new hypotheses about which natural processes to reproduce and why their effects might extend life.
Stated in the chain - Goal pillarstep 02 of 04
The intended output is a defined set of new interventions that reproduce natural processes for possible lifespan extension.
Rests on: The master question requests exactly this kind of candidate set and an explanation of its possible benefits.
Stated in the chain - Gap questionstep 03 of 04
Timely completion of tissue repair might extend life more than stronger repair if both restore tissue equally well at first, but only completion limits later expansion of pathological clones, groups of abnormal cells descended from a common cell.
Rests on: The broad search permits considering repair completion as a process to reproduce, but supplies no evidence for its advantage over stronger repair.
AssumptionThe comparison takes selective limitation of later abnormal cell expansion, despite equal early repair, as its conditional premise. Whether that difference exists and produces longer life remains open.
- Hypothesisstep 04 of 04
Restoring oxygen use in mature colonocytes, the cells lining the colon, is proposed to leave less oxygen for bacteria and thereby reduce repeated inflammatory injury, abnormal cell expansion and deaths from tumors.S2
Rests on: The preceding question supplies the distinction between completing and strengthening repair. The 2021 mBio study supplies a narrower experimental basis: mesalazine restored low oxygen in the gut lining and limited oxygen-dependent growth of Escherichia coli, a bacterial species, through peroxisome proliferator-activated receptor gamma (PPARγ), a receptor involved in regulating cell activity. That study does not establish increased oxygen consumption by mature colon cells after repair, late local treatment, restriction of abnormal cell groups or reduced tumor mortality.
Supported by literature
What is carried, and what is not. The supplied 2021 mBio study supports an adjoining part of the proposed sequence: receptor-dependent restoration of low oxygen in the gut lining and restriction of bacterial growth that depends on oxygen; it does not establish the proposed return to mature-cell fuel use after repair or the later effects on abnormal cell expansion and tumor deaths. No supplied source establishes the complete sequence from late completion of repair to longer life.
Where the reasoning is carried by something unstated · 1
- Gap question. The comparison takes selective limitation of later abnormal cell expansion, despite equal early repair, as its conditional premise. Whether that difference exists and produces longer life remains open.
How a result here could mislead · 3
- A beneficial response to mesalazine could be credited to oxygen consumption even if another drug effect produced it. Reduced inflammation alone would also fail to separate this route from the rival involving intestinal alkaline phosphatase, an enzyme that removes phosphate groups from bacterial components that stimulate inflammation. What closes it: The proposed genetic checks must establish dependence on the receptor and on oxygen-consuming processes in colon cells, while oxygen availability and bacterial oxygen use are measured separately. The comparison must preserve early repair and intestinal alkaline phosphatase activity, and protection must be recoverable by independently restoring low oxygen availability; matched bacterial variants lacking the relevant oxygen-use advantage provide the additional separation specified in the proposal.
- Loss of protection after blocking colon-cell oxygen use could reflect impaired repair or new tissue damage rather than interruption of the proposed oxygen route. Conversely, retained protection would be ambiguous if the block failed to change oxygen use. What closes it: The block must be shown to alter colon-cell oxygen use, with its effects on tissue condition and early repair checked in matched controls. Independent restoration of low oxygen must be verified directly before its success or failure is interpreted as evidence about the mechanism.
- Smaller abnormal cell groups during treatment could be mistaken for a lasting reduction in tumor risk or an increase in lifespan, although the rival explanation predicts that growth resumes after treatment stops. What closes it: Follow-up must distinguish growth during treatment from growth after withdrawal and must measure tumor deaths and survival to support the lifespan claim. The supplied testing outline specifies neither a follow-up duration nor a criterion for durable protection.
What would make this wrong. The proposal explicitly identifies continued protection when oxygen availability and bacterial oxygen use are experimentally held fixed as a refutation of its claimed route. Failure of independently restored low oxygen to recover protection after verified suppression of colon-cell oxygen use, with early repair preserved, would also contradict its distinguishing prediction. Even if the oxygen route worked, unchanged tumor mortality and survival despite smaller abnormal cell groups would break the further claim that this route extends life.
What it would change. If this held, reproducing the chemical conditions created by mature gut cells would become a candidate way to complete repair and restrain later abnormal growth. Work on lifespan-extending interventions would need to compare that function with stronger repair while holding early recovery equal. Success in joint cultures of gut cells and bacteria, or in mice with a specified bacterial community, would still leave longer life, superiority over repair enhancement and relevance to humans unestablished.
Sources read · 6
Repurposing a Drug Targeting Inflammatory Bowel Disease for Lowering Hypertension. · Journal of the American Heart Association · 2022
“This reduction in blood pressure was accompanied by increased activity of PPARγ, increased expression of energy metabolism-related genes, and lowering of the Firmicutes/Bacteroidetes ratio in the colon, the reduction of which is a marker for the correction of gut dysbiosis.”
Does not settle: The abstract does not establish restored oxygen consumption or fatty-acid oxidation in mature colonocytes, PPARγ or oxidative-metabolism dependence, effects after regeneration, local late treatment, restriction of pathological clones, prevention of recurrent inflammatory injury, or reduced tumor mortality. The experiment used oral 5-ASA for 4 weeks in male hypertensive rats and evaluated blood pressure, gene expression, PPARγ activity, and microbiota composition.
“Here, we show that 5-ASA restored epithelial hypoxia in DSS-treated mice and limited an aerobic-respiration-dependent expansion of E. coli in the colonic microbiota by activating epithelial PPAR-γ signaling.”
Does not settle: Источник не устанавливает, что позднее локальное применение месалазина после завершения регенерации восстанавливает окисление жирных кислот или непосредственно повышает потребление кислорода зрелыми колоноцитами. Также он не оценивает патологические клоны, повторные повреждения после регенерации, опухолевую смертность или стабилизацию SPV_3.
Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. · Danish medical journal · 2015
“Moreover, rectal application of rosiglitazone induced PPARγ signalling in the epithelium in vivo, supporting the view that activation of PPARγ may be a new potential therapeutic target in the treatment of UC.”
Does not settle: Источник не устанавливает, что месалазин восстанавливает потребление кислорода или окисление жирных кислот колоноцитами через PPARγ. Он также не исследует доступность кислорода для бактерий, рост факультативных анаэробов, патологические клоны, повторное повреждение после регенерации или опухолевую смертность.
Improvement of replication fidelity by certain mesalazine derivatives. · International journal of oncology · 2012
“The objective of this study was to test five novel derivatives (compounds 2-14, 2-17, 2-28, 2-34L, 2-39) for their effect on cell proliferation, their capability to scavenge superoxide anions, to induce a cell cycle arrest and to improve replication fidelity in cultured colorectal cells.”
Does not settle: Источник не исследует месалазин как локальный поздний миметик завершения регенерации, потребление кислорода или окисление жирных кислот зрелыми колоноцитами, зависимость от PPARγ, химическую среду кишечника, рост факультативных анаэробов, повторное воспалительное повреждение, патологические клоны или опухолевую смертность. Описаны только отдельные производные месалазина и клеточные показатели в культивируемых клетках колоректального рака.
Medical therapies for ulcerative colitis and Crohn's disease. · Current gastroenterology reports · 2000
“Important observations in ulcerative colitis (UC) over the past year include evidence of a protective effect of 5-aminosalicylic acid (5-ASA) with respect to colorectal cancer”
Does not settle: The abstract does not establish whether mesalazine restores colonocyte oxygen consumption, acts through PPARγ or fatty-acid oxidation, changes bacterial respiration, limits pathological clones or recurrent injury, or reduces tumor mortality. It also provides no treatment timing, dose, population details, follow-up duration, or quantitative effect.
Growth inhibition of colon cancer cells by compounds affecting AMPK activity. · World journal of gastrointestinal oncology · 2014
“Further study in the absence of cells revealed that the effect was an artifact due to inhibition of the enzyme-linked glucose assay.”
Does not settle: Источник изучает опухолевые клеточные линии толстой кишки и не устанавливает влияние месалазина на потребление кислорода зрелыми колоноцитами, окисление жирных кислот, зависимость от PPARγ, состав кишечной микробиоты, повторное воспалительное повреждение, патологические клоны или опухолевую смертность.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Can mimicking timely repair completion extend life more than boosting repair by limiting later growth of abnormal cell groups?
Original wording · exactly as the pipeline generated it
Может ли миметик своевременного завершения регенерации продлевать жизнь сильнее миметика её усиления, если при одинаковом раннем восстановлении только первый ограничивает последующее расширение патологических клонов?
What this question is asking
The question compares two ways of copying the body's tissue-repair processes: strengthening repair and bringing it to a timely end. It asks whether repeated treatments that promote completion could extend remaining life more than treatments that strengthen repair, when both restore the tissue's protective barrier equally well at first. It assumes that only the completion treatment limits the later expansion of pathological clones, meaning groups of cells descended from one cell that have disease-associated properties. It also asks whether tissue aging changes which phase of repair determines the long-term benefit or harm.
- Mimetic
- An intervention intended to reproduce some effect of a natural biological process. Here it refers to copying either stronger tissue repair or its timely completion; no particular substance or intervention is specified.
- Regeneration or tissue repair
- The processes through which damaged tissue recovers. The question distinguishes an early period of recovery from the later ending of repair activity, without establishing precise boundaries between these phases.
- Timely repair completion
- Ending repair activity at a time that preserves its useful recovery effects. The supplied material does not specify how that time is recognized or measured.
- Tissue barrier
- A tissue's protective separation between compartments or between the body and its surroundings. Restoring this function is the proposed early benefit, but the specific tissue and measurement are not identified.
- Pathological clone
- A group of cells descended from a common ancestor cell and described as having disease-associated properties. Clone expansion means that this group grows; the input does not specify which properties make a clone pathological or whether every such clone leads to cancer.
- Remaining lifespan
- The length of life after a specified starting point, such as treatment initiation. It is distinct from early tissue recovery or the amount of abnormal cell growth.
- Tissue aging
- Changes in tissue as it grows older. The question asks whether these changes alter the treatment comparison, but supplies no age categories or measure of tissue aging.
- Signaling pathway
- A connected sequence of cellular signals that influences what cells do. S4 distinguishes which repair-related pathway is active from how long that activity continues.
- Stem cell
- A cell capable of maintaining a cell supply and producing cells that contribute to tissue renewal. S2's model concerns the subset activated in association with repair, rather than all stem cells.
- Time-weighted measure
- A measure that accounts for how long different values persist. In S2, the prediction concerns activated cell numbers over time rather than a single cell count.
- Inflammation and its resolution
- Inflammation is a biological response to injury or harmful stimuli; resolution is the process by which that response ends. S3 hypothesizes impaired resolution, which is related to, but does not establish, the proposed comparison of repair treatments.
- Mutation
- A change in a cell's genetic material. S3 hypothesizes a type of mutation that interferes with the ending of inflammation.
- Cancer-promoting or carcinogenic
- Contributing to the development of cancer. S4 uses this outcome to distinguish potentially harmful prolonged repair signaling from safe regeneration; it does not measure the lifespan effects of the proposed treatments.
- Acute and chronic injury
- Acute injury occurs over a relatively short period, while chronic injury persists or recurs. These are the injury contexts identified for S4, rather than specified treatment schedules.
At equal early recovery, only a mimetic of timely regeneration completion limits subsequent expansion of pathological clones.
A mimetic is a treatment intended to reproduce a natural process; here, the two processes are strengthening tissue repair and ending it at the appropriate time. The assumption is that both treatments initially restore tissue function equally well, but only the completion treatment restrains later growth of disease-associated cell families. If established, this would make later cell growth a possible explanation for a difference in remaining lifespan.
S4 supports a narrower timing-related proposition: in its discussion of liver cancer, it states that the duration of repair-related signaling determines whether regeneration remains safe or becomes cancer-promoting. It does not establish equal early recovery under two mimetics, or that only a completion mimetic limits pathological clones. S2 supplies a theoretical connection between sustained activation of repair-associated stem cells and cancer risk, rather than evidence for this treatment comparison. The supplied sources therefore support part of the rationale, but not the asserted comparative result.S4S2
The same question asked without the part nothing read establishes:
- When two treatments restore a tissue barrier equally well at first, does mimicking timely repair completion extend remaining life more than strengthening repair?
- How do treatments that promote repair completion versus stronger repair differ in later abnormal cell expansion and remaining lifespan?
- Does tissue aging change the long-term effects of strengthening repair compared with promoting its timely completion?
- Timely completion extends life more Under the question's assumptions, both treatments would deliver the same early recovery, while the completion treatment would leave less subsequent abnormal cell expansion. A longer remaining lifespan would be consistent with that later difference outweighing any benefit of continued repair, although the lifespan difference alone would not prove its cause.
- Both extend life equally Even if the completion treatment limited abnormal cell expansion more effectively, that difference would not produce a greater lifespan benefit over the period measured. Early repair, later cell growth and remaining lifespan would therefore be distinct outcomes rather than interchangeable measures of success.
- Stronger repair extends life more Under the same assumed early recovery and clone-growth difference, stronger repair would nevertheless produce the better survival outcome. This would mean that restricting abnormal cell expansion was insufficient to determine the overall lifespan effect; the supplied sources do not establish what would account for that result.
- The ranking changes with tissue age The same early recovery and later difference in abnormal cell growth could accompany different lifespan rankings in younger and older tissue. A result established at one tissue age would then fail to settle the comparison at another; the supplied sources do not establish whether such a reversal occurs.
The proposed benefit begins with restoring a damaged tissue barrier, allowing the tissue to perform its protective role again. The question then separates that early recovery from what happens to abnormal cell groups afterward. If equally effective early repair is followed by different amounts of harmful cell expansion, early recovery alone would not establish which treatment has the better long-term outcome. However, even less abnormal cell expansion would not by itself establish longer life; that final connection remains unmeasured in the supplied evidence.
S-узлы уровня RL-1 поддерживают усиление регенерации, её последующее торможение и возможность клонального отбора; общий долгосрочный исход неизвестен.
Повторные циклы миметика восстанавливают барьер и увеличивают оставшуюся жизнь при отсутствии ускоренного расширения патологических клонов.
Не установлено, какая фаза определяет знак долгосрочного эффекта при одинаковой ранней пользе и меняется ли это со старением ткани.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Миметик завершения регенерации может ограничивать патологические клоны через восстановление потребления кислорода зрелыми колоноцитами. Затянувшаяся регенеративная программа сохраняет обмен, при котором больше кислорода доступно кишечным бактериям; это поддерживает респираторный рост факультативных анаэробов и повторное воспалительное повреждение. Физиологический прототип — возвращение зрелого эпителия к окислению жирных кислот после восстановления. Кандидатный миметик — локальное позднее воздействие месалазином с проверкой зависимости от рецептора, активируемого пролифераторами пероксисом, типа гамма (PPARγ), и от окислительного обмена колоноцитов. Предполагаемая польза определяется восстановлением химической среды кишечника, затем уменьшением повторных повреждений и опухолевой смертности. Стабилизируется SPV_3.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
При одинаковом раннем восстановлении и сохранённой активности кишечной щелочной фосфатазы преимущество позднего миметика исчезнет при избирательном подавлении окислительного обмена колоноцитов. Независимое восстановление низкой доступности кислорода вернёт защиту. В определённом микробном сообществе замена бактерий на сопоставимые варианты, лишённые соответствующего преимущества дыхания, должна резко уменьшить различие между усилением и завершением регенерации. Если защита сохраняется при экспериментально фиксированных кислороде и бактериальном дыхании, гипотеза опровергнута.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies observable loss and restoration of protection, a qualitative reduction in a difference, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Механизм можно разделить в совместных культурах эпителия и бактерий с управляемым кислородом, затем в мышах с определённой микробиотой. Поскольку месалазин имеет несколько эффектов, одного положительного ответа на препарат недостаточно: необходимы генетическая проверка зависимости и независимое восстановление кислородного режима.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
При одинаковом раннем восстановлении и сохранённой активности кишечной щелочной фосфатазы преимущество позднего миметика исчезнет при избирательном подавлении окислительного обмена колоноцитов. Независимое восстановление низкой доступности кислорода вернёт защиту. В определённом микробном сообществе замена бактерий на сопоставимые варианты, лишённые соответствующего преимущества дыхания, должна резко уменьшить различие между усилением и завершением регенерации. Если защита сохраняется при экспериментально фиксированных кислороде и бактериальном дыхании, гипотеза опровергнута.
- Rival 01 of 04What would separate them
Brief breaks in genetic material may complete intestinal cell maturation and curb harmful growth predicts: При одинаковом раннем восстановлении и одинаковом позднем снижении пролиферации выключение каталитической активности CAD устранит устойчивую дифференцировку и последующее ограничение патологических линий. Возвращение кратковременной активности нормального CAD восстановит оба эффекта; каталитически неактивный вариант окажется бесполезен. Решающее наблюдение: клетки с зарегистрированными кратковременными разрывами останутся живыми, завершат дифференцировку и дадут меньше патологических потомков. Если они преимущественно погибают либо польза сохраняется при выключенном CAD, предложенный механизм опровергнут.
- Rival 02 of 04What would separate them
Timely regeneration completion may limit harmful clones by reducing mobile DNA insertions predicts: При равном суммарном числе делений позднее подавление LINE-1 уменьшит число новых подтверждённых вставок и патологическое расширение линий, сохранив раннее восстановление. Оно также устранит дополнительное преимущество миметика завершения, если оба действуют через один механизм. Напротив, сохранение преимущества завершения при практически устранённой ретротранспозиции опровергнет её определяющую роль. Перестановка последовательности циклов при одинаковом наборе нагрузок отдельно проверит предсказание модели накопления.
- Rival 03 of 04What would separate them
Restoring intestinal alkaline phosphatase may limit pathological growth after regeneration predicts: При одинаковой проницаемости эпителия, одинаковом содержании кислорода и одинаковом количестве бактерий активный фермент уменьшит воспалительную активность кишечного содержимого и позднее расширение патологических линий; каталитически неактивный фермент этого не сделает. Подавление эндогенной кишечной щелочной фосфатазы устранит преимущество завершения, а добавление активного фермента восстановит его. Сохранение преимущества при отсутствии измеримого дефосфорилирования опровергнет гипотезу.
- What would separate them
A late aryl hydrocarbon receptor signal may pause clone growth without extending life predicts: После полного прекращения воздействия патологические линии из обеих групп покажут сопоставимую способность к повторному росту в общей среде и сопоставимую опухолеобразующую способность. При продолжительном наблюдении до конца жизни различие в размерах клонов не перейдёт в преимущество общей выживаемости. Устойчивое уменьшение опухолевого потенциала после отмены вместе с увеличением оставшейся жизни опровергнет эту гипотезу в пользу одного из механизмов полноценного завершения.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.